{"transactions":[{"id":1578745,"issuer":{"id":93100,"kind":"organization","name":"Motus GI Holdings, Inc.","symbol":"MOTS"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-13T08:03:48.000Z","date":"2024-03-05","kind":"grant","planned":false,"acquired":true,"shares":23205,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the \"Plan\"). The option vests in its entirety on the first anniversary of the date of grant, March 5, 2025. The exercise price is based on the closing price for the shares of the common stock on the date of grant in accordance with the terms of the Plan."}],"balance_after":23205,"derivative":{"exercise_price":0.622,"expiration_date":"2034-03-05","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":23205},"source":{"system":"sec-edgar","filing":"0001493152-24-009772","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686850/000149315224009772/ownership.xml","form_type":"4"}},{"id":1589469,"issuer":{"id":93373,"kind":"organization","name":"Ambrx Biopharma, Inc.","symbol":"AMAM"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-03-07T17:41:36.000Z","date":"2024-03-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":55571,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The Company Common Stock subject to the Company Options vest as follows: (i) 1/6 of the Company Common Stock vested on January 5, 2024, and the remainder vests in ten (10) equal quarterly installments following such date."}],"balance_after":0,"derivative":{"exercise_price":16.66,"expiration_date":"2033-07-05","underlying":"Common Stock","underlying_shares":55571},"source":{"system":"sec-edgar","filing":"0000950170-24-028182","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1990550/000095017024028182/ownership.xml","form_type":"4"}},{"id":1589468,"issuer":{"id":93373,"kind":"organization","name":"Ambrx Biopharma, Inc.","symbol":"AMAM"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-03-07T17:41:36.000Z","date":"2024-03-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60714,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"These Company Options are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.96,"expiration_date":"2032-02-23","underlying":"Common Stock","underlying_shares":60714},"source":{"system":"sec-edgar","filing":"0000950170-24-028182","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1990550/000095017024028182/ownership.xml","form_type":"4"}},{"id":1589467,"issuer":{"id":93373,"kind":"organization","name":"Ambrx Biopharma, Inc.","symbol":"AMAM"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-03-07T17:41:36.000Z","date":"2024-03-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":121427,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The Company Common Stock subject to the Company Options vest as follows: (i) twenty-five (25) percent of the Company Common Stock vested on February 23, 2023, and (ii) the remainder vests in thirty-six equal monthly installments following such date."}],"balance_after":0,"derivative":{"exercise_price":1.96,"expiration_date":"2032-02-23","underlying":"Common Stock","underlying_shares":121427},"source":{"system":"sec-edgar","filing":"0000950170-24-028182","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1990550/000095017024028182/ownership.xml","form_type":"4"}},{"id":1589466,"issuer":{"id":93373,"kind":"organization","name":"Ambrx Biopharma, Inc.","symbol":"AMAM"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-03-07T17:41:36.000Z","date":"2024-03-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":367799,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Company Common Stock subject to the options to purchase shares of Company Common Stock (each, a \"Company Option\") vest as follows: (i) twenty-five (25) percent of the Company Common Stock vested on June 30, 2022, and (ii) the remainder vests in thirty-six equal monthly installments following such date."}],"balance_after":0,"derivative":{"exercise_price":1.96,"expiration_date":"2031-09-01","underlying":"Common Stock","underlying_shares":367799},"source":{"system":"sec-edgar","filing":"0000950170-24-028182","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1990550/000095017024028182/ownership.xml","form_type":"4"}},{"id":1589465,"issuer":{"id":93373,"kind":"organization","name":"Ambrx Biopharma, Inc.","symbol":"AMAM"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-03-07T17:41:36.000Z","date":"2024-03-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each of these restricted stock units (\"RSUs\") represents a contingent right to receive one share of the Company Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These RSUs vest as follows: (i) one-sixth (1/6) of the RSUs will vest on the six (6)-month anniversary of the grant date of December 11, 2023, and (ii) one-twelfth (1/12) of the RSUs will vest on a quarterly basis thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"These RSUs vest as follows: (i) one-sixth (1/6) of the RSUs will vest on the six (6)-month anniversary of the grant date of December 11, 2023, and (ii) one-twelfth (1/12) of the RSUs will vest on a quarterly basis thereafter."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-24-028182","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1990550/000095017024028182/ownership.xml","form_type":"4"}},{"id":1589464,"issuer":{"id":93373,"kind":"organization","name":"Ambrx Biopharma, Inc.","symbol":"AMAM"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-03-07T17:41:36.000Z","date":"2024-03-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":107143,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each of these restricted stock units (\"RSUs\") represents a contingent right to receive one share of the Company Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These RSUs vest as follows: (i) one-third (1/3) of the RSUs will vest on the 12-month anniversary of April 26, 2023 (the \"Grant Date\"), (ii) one-third (1/3) of the RSUs will vest on the 24-month anniversary of the Grant Date, and (iii) one-third (1/3) of the RSUs will vest on the 36-month anniversary of the Grant Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These RSUs vest as follows: (i) one-third (1/3) of the RSUs will vest on the 12-month anniversary of April 26, 2023 (the \"Grant Date\"), (ii) one-third (1/3) of the RSUs will vest on the 24-month anniversary of the Grant Date, and (iii) one-third (1/3) of the RSUs will vest on the 36-month anniversary of the Grant Date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":107143},"source":{"system":"sec-edgar","filing":"0000950170-24-028182","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1990550/000095017024028182/ownership.xml","form_type":"4"}},{"id":1589463,"issuer":{"id":93373,"kind":"organization","name":"Ambrx Biopharma, Inc.","symbol":"AMAM"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-07T17:41:36.000Z","date":"2024-03-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22936,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson (\"J&J\"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of March 7, 2024 (such date and time of such Merger, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding share of common stock of the Issuer (\"Company Common Stock\") reported in this Form 4 was converted into the right to receive an amount equal to $28.00 per share in cash (the \"Merger Consideration\"), without interest and less any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-028182","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1990550/000095017024028182/ownership.xml","form_type":"4"}},{"id":1716613,"issuer":{"id":93373,"kind":"organization","name":"Ambrx Biopharma, Inc.","symbol":"AMAM"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-12-11T17:17:24.000Z","date":"2023-12-11","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") payable in common stock of the Issuer granted to the Reporting Person on December 11, 2023 (the \"Grant Date\"). The RSUs were granted in connection with the completion of the year-end review process and will be issued pursuant to the Company's Amended and Restated 2021 Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest over thirty-six (36) months as follows: (i) one-sixth (1/6) of the RSUs will vest on the six (6)-month anniversary of the Grant Date, and (ii) one-twelfth (1/12) of the RSUs will vest on a quarterly basis thereafter."}],"balance_after":545776,"source":{"system":"sec-edgar","filing":"0000950170-23-069447","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1990550/000095017023069447/ownership.xml","form_type":"4"}},{"id":1753262,"issuer":{"id":93373,"kind":"organization","name":"Ambrx Biopharma, Inc.","symbol":"AMAM"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-10-31T17:00:15.000Z","date":"2023-10-27","kind":"sale","planned":true,"acquired":false,"shares":12778,"price":9.82,"value":125479.96,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reflects an adjustment in connection with the holding company reorganization resulting in Ambrx Biopharma, Inc. (\"Ambrx\") becoming a Delaware corporation (the \"Domestication\").  Pursuant to the transactions contemplated by the Domestication, each Ordinary Share of the previous holding company (Ambrx Biopharma Inc., a Cayman Islands company) converted into one-seventh (1/7th) of a share of common stock of Ambrx. Represents Restricted Stock Units (\"RSUs\") payable in Ambrx common stock granted to the Reporting Person as previously disclosed."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of the RSUs. The sale is mandated by Ambrx's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person. The sale is being made pursuant to the Reporting Person's effective 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.70 to $9.99. The Reporting Person undertakes to provide to Ambrx, any security holder of Ambrx or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects an adjustment in connection with the holding company reorganization resulting in Ambrx Biopharma, Inc. (\"Ambrx\") becoming a Delaware corporation (the \"Domestication\").  Pursuant to the transactions contemplated by the Domestication, each Ordinary Share of the previous holding company (Ambrx Biopharma Inc., a Cayman Islands company) converted into one-seventh (1/7th) of a share of common stock of Ambrx. Represents Restricted Stock Units (\"RSUs\") payable in Ambrx common stock granted to the Reporting Person as previously disclosed."}],"balance_after":130079,"source":{"system":"sec-edgar","filing":"0000950170-23-056944","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1990550/000095017023056944/ownership.xml","form_type":"4"}},{"id":1833015,"issuer":{"id":109604,"kind":"organization","name":"Ambrx Biopharma Inc.","symbol":"AMAM"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-07-07T16:05:51.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":389000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The options will have an exercise price per share equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares (\"ADSs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/6 of the Ordinary Shares subject to the option vest on January 5, 2024, and the remainder vests in ten (10) equal quarterly installments following such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven Ordinary Shares of the Issuer."}],"balance_after":389000,"derivative":{"exercise_price":2.38,"expiration_date":"2033-07-05","underlying":"Ordinary Shares","underlying_shares":389000},"source":{"system":"sec-edgar","filing":"0000950170-23-032230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1836056/000095017023032230/ownership.xml","form_type":"4"}},{"id":1911414,"issuer":{"id":109604,"kind":"organization","name":"Ambrx Biopharma Inc.","symbol":"AMAM"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Fin. & Operating Officer"}}],"security":"Ordinary Shares","published_at":"2023-04-28T18:00:38.000Z","date":"2023-04-26","kind":"grant","planned":false,"acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares of the Issuer may be represented by American Depositary Shares (\"ADSs\"). Each ADS represents seven Ordinary Shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents grant of Restricted Stock Units (the \"RSUs\") payable solely in Ordinary Shares of the Issuer that vest as follows: (i) 25% of the RSUs will vest on the six-month anniversary of the grant date of April 26, 2023 (the \"Grant Date\"), (ii) 25% of the RSUs will vest on the 12-month anniversary of the Grant Date, (iii) 25% of the RSUs will vest on the 24-month anniversary of the Grant Date, and (iv) 25% of the RSUs will vest on the 36-month anniversary of the Grant Date."}],"balance_after":1000000,"source":{"system":"sec-edgar","filing":"0001209191-23-026101","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1836056/000120919123026101/doc4.xml","form_type":"4"}},{"id":2040469,"issuer":{"id":109604,"kind":"organization","name":"Ambrx Biopharma Inc.","symbol":"AMAM"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Fin. & Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-31T18:16:32.000Z","date":"2023-01-27","kind":"grant","acquired":true,"shares":425000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The option held by the reporting person was amended to reduce the exercise price."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares of the Issuer may be represented by American Depositary Shares (\"ADSs\"). Each ADS represents seven Ordinary Shares of the Issuer."}],"balance_after":425000,"derivative":{"exercise_price":0.28,"exercise_date":"2023-02-23","expiration_date":"2032-02-22","underlying":"Ordinary Shares","underlying_shares":425000},"source":{"system":"sec-edgar","filing":"0001209191-23-005791","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1836056/000120919123005791/doc4.xml","form_type":"4"}},{"id":2040468,"issuer":{"id":109604,"kind":"organization","name":"Ambrx Biopharma Inc.","symbol":"AMAM"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Fin. & Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-31T18:16:32.000Z","date":"2023-01-27","kind":"disposition_to_issuer","acquired":false,"shares":425000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The option held by the reporting person was amended to reduce the exercise price."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares of the Issuer may be represented by American Depositary Shares (\"ADSs\"). Each ADS represents seven Ordinary Shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0.64,"exercise_date":"2023-02-23","expiration_date":"2032-02-22","underlying":"Ordinary Shares","underlying_shares":425000},"source":{"system":"sec-edgar","filing":"0001209191-23-005791","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1836056/000120919123005791/doc4.xml","form_type":"4"}},{"id":2040467,"issuer":{"id":109604,"kind":"organization","name":"Ambrx Biopharma Inc.","symbol":"AMAM"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Fin. & Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-31T18:16:32.000Z","date":"2023-01-27","kind":"grant","acquired":true,"shares":850000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The option held by the reporting person was amended to reduce the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twenty-five percent of the Ordinary Shares subject to the option vests on February 23, 2023, and the remainder vests in thirty-six equal monthly installments following such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares of the Issuer may be represented by American Depositary Shares (\"ADSs\"). Each ADS represents seven Ordinary Shares of the Issuer."}],"balance_after":850000,"derivative":{"exercise_price":0.28,"expiration_date":"2032-02-22","underlying":"Ordinary Shares","underlying_shares":850000},"source":{"system":"sec-edgar","filing":"0001209191-23-005791","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1836056/000120919123005791/doc4.xml","form_type":"4"}},{"id":2040466,"issuer":{"id":109604,"kind":"organization","name":"Ambrx Biopharma Inc.","symbol":"AMAM"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Fin. & Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-31T18:16:32.000Z","date":"2023-01-27","kind":"disposition_to_issuer","acquired":false,"shares":850000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The option held by the reporting person was amended to reduce the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twenty-five percent of the Ordinary Shares subject to the option vests on February 23, 2023, and the remainder vests in thirty-six equal monthly installments following such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares of the Issuer may be represented by American Depositary Shares (\"ADSs\"). Each ADS represents seven Ordinary Shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0.64,"expiration_date":"2032-02-22","underlying":"Ordinary Shares","underlying_shares":850000},"source":{"system":"sec-edgar","filing":"0001209191-23-005791","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1836056/000120919123005791/doc4.xml","form_type":"4"}},{"id":2040465,"issuer":{"id":109604,"kind":"organization","name":"Ambrx Biopharma Inc.","symbol":"AMAM"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Fin. & Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-31T18:16:32.000Z","date":"2023-01-27","kind":"grant","acquired":true,"shares":2574596,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The option held by the reporting person was amended to reduce the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of the Ordinary Shares subject to the option vested on June 30, 2022, and the remainder vests in thirty-six equal monthly installments following such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares of the Issuer may be represented by American Depositary Shares (\"ADSs\"). Each ADS represents seven Ordinary Shares of the Issuer."}],"balance_after":2574596,"derivative":{"exercise_price":0.28,"expiration_date":"2031-09-01","underlying":"Ordinary Shares","underlying_shares":2574596},"source":{"system":"sec-edgar","filing":"0001209191-23-005791","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1836056/000120919123005791/doc4.xml","form_type":"4"}},{"id":2040464,"issuer":{"id":109604,"kind":"organization","name":"Ambrx Biopharma Inc.","symbol":"AMAM"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Fin. & Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-31T18:16:32.000Z","date":"2023-01-27","kind":"disposition_to_issuer","acquired":false,"shares":2574596,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The option held by the reporting person was amended to reduce the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of the Ordinary Shares subject to the option vested on June 30, 2022, and the remainder vests in thirty-six equal monthly installments following such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares of the Issuer may be represented by American Depositary Shares (\"ADSs\"). Each ADS represents seven Ordinary Shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":2.56,"expiration_date":"2031-09-01","underlying":"Ordinary Shares","underlying_shares":2574596},"source":{"system":"sec-edgar","filing":"0001209191-23-005791","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1836056/000120919123005791/doc4.xml","form_type":"4"}},{"id":2401679,"issuer":{"id":93100,"kind":"organization","name":"Motus GI Holdings, Inc.","symbol":"MOTS"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-11T17:06:16.000Z","date":"2022-02-10","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the \"2016 Plan\"). The option becomes exercisable as to 100% of the shares on February 10, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan."}],"balance_after":50000,"derivative":{"exercise_price":0.46,"expiration_date":"2032-02-10","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-004051","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686850/000149315222004051/ownership.xml","form_type":"4"}},{"id":2440044,"issuer":{"id":93100,"kind":"organization","name":"Motus GI Holdings, Inc.","symbol":"MOTS"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2022-01-07T16:45:21.000Z","date":"2022-01-05","kind":"grant","acquired":true,"shares":82500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 5, 2022, Reporting Person was granted 82,500 shares of Common Stock as compensation in lieu of cash for Reporting Persons service as a director for calendar year 2022, pursuant to the Company's non-employee director compensation policy. The grant was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the \"2016 Plan\")."}],"balance_after":100709,"source":{"system":"sec-edgar","filing":"0001493152-22-000691","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686850/000149315222000691/ownership.xml","form_type":"4"}},{"id":2657157,"issuer":{"id":93100,"kind":"organization","name":"Motus GI Holdings, Inc.","symbol":"MOTS"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-23T16:13:44.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option award was made in accordance with the terms of the issuer's 2016 Plan. The option becomes exercisable as to 50% of the shares on June 22, 2022, and the remaining shares will become exercisable on June 22, 2023."}],"balance_after":50000,"derivative":{"exercise_price":1.04,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001213900-21-033779","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1686850/000121390021033779/ownership.xml","form_type":"4"}},{"id":2657156,"issuer":{"id":93100,"kind":"organization","name":"Motus GI Holdings, Inc.","symbol":"MOTS"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-06-23T16:13:44.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":18209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On June 22, 2021, Reporting Person was granted 18,209 shares of Common Stock as compensation in lieu of cash for Reporting Persons service as a director for the remainder of calendar year 2021, pursuant to the Company's non-employee director compensation policy. The grant was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the \"2016 Plan\")"}],"balance_after":18209,"source":{"system":"sec-edgar","filing":"0001213900-21-033779","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686850/000121390021033779/ownership.xml","form_type":"4"}},{"id":2908292,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-13T16:19:25.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":11364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the award recipient's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the option shall vest as follows: twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on August 27, 2019, and thereafter the remaining shares subject to the option shall vest and become exercisable in equal monthly installments over thirty six (36) months, such that the option will be fully vested and exercisable on August 27, 2022."}],"balance_after":165907,"derivative":{"exercise_price":3.07,"expiration_date":"2028-08-27","underlying":"Common Stock","underlying_shares":11364},"source":{"system":"sec-edgar","filing":"0001209191-21-003421","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674905/000120919121003421/doc4.xml","form_type":"4"}},{"id":2908291,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-13T16:19:25.000Z","date":"2021-01-12","kind":"sale","acquired":false,"shares":16364,"price":15,"value":245460.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 4, 2020."}],"balance_after":15410,"source":{"system":"sec-edgar","filing":"0001209191-21-003421","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674905/000120919121003421/doc4.xml","form_type":"4"}},{"id":2908290,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-13T16:19:25.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":11364,"price":3.07,"value":34887.48,"ownership":{"direct":true},"balance_after":31774,"source":{"system":"sec-edgar","filing":"0001209191-21-003421","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674905/000120919121003421/doc4.xml","form_type":"4"}},{"id":2915824,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-06T20:25:01.000Z","date":"2021-01-04","kind":"exercise","acquired":false,"shares":22729,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the award recipient's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the option shall vest as follows: twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on August 27, 2019, and thereafter the remaining shares subject to the option shall vest and become exercisable in equal monthly installments over thirty six (36) months, such that the option will be fully vested and exercisable on August 27, 2022."}],"balance_after":177271,"derivative":{"exercise_price":3.07,"expiration_date":"2028-08-27","underlying":"Common Stock","underlying_shares":22729},"source":{"system":"sec-edgar","filing":"0001209191-21-002393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674905/000120919121002393/doc4.xml","form_type":"4"}},{"id":2915823,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-06T20:25:01.000Z","date":"2021-01-04","kind":"sale","acquired":false,"shares":39271,"price":13.6217,"value":534937.7807,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 4, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 39,271 shares sold in the price range of $13.31 to $14.015 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":20410,"source":{"system":"sec-edgar","filing":"0001209191-21-002393","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674905/000120919121002393/doc4.xml","form_type":"4"}},{"id":2915822,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-06T20:25:01.000Z","date":"2021-01-04","kind":"exercise","acquired":true,"shares":22729,"price":3.07,"value":69778.03,"ownership":{"direct":true},"balance_after":59681,"source":{"system":"sec-edgar","filing":"0001209191-21-002393","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674905/000120919121002393/doc4.xml","form_type":"4"}},{"id":3069712,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-08-04T21:05:32.000Z","date":"2020-08-02","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of NantKwest, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units (\"RSUs\") will vest as follows: 25% of the RSUs will vest on August 2, 2019, and 25% of the RSUs will vest annually thereafter, such that the award will be fully vested on August 2, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units (\"RSUs\") will vest as follows: 25% of the RSUs will vest on August 2, 2019, and 25% of the RSUs will vest annually thereafter, such that the award will be fully vested on August 2, 2022."}],"balance_after":20000,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-044914","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674905/000120919120044914/doc4.xml","form_type":"4"}},{"id":3069711,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-08-04T21:05:32.000Z","date":"2020-08-02","kind":"tax_withholding","acquired":false,"shares":3458,"price":11.18,"value":38660.44,"ownership":{"direct":true},"balance_after":36952,"source":{"system":"sec-edgar","filing":"0001209191-20-044914","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674905/000120919120044914/doc4.xml","form_type":"4"}},{"id":3069710,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-08-04T21:05:32.000Z","date":"2020-08-02","kind":"exercise","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of NantKwest, Inc. common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 2, 2020, 10,000 of the reporting person's restricted stock units vested. The closing price of the issuer's common stock on July 31, 2020 was the price used to calculate the shares withheld."}],"balance_after":40410,"source":{"system":"sec-edgar","filing":"0001209191-20-044914","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674905/000120919120044914/doc4.xml","form_type":"4"}},{"id":3196446,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-03-24T17:47:37.000Z","date":"2020-03-23","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of NantKwest, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units (\"RSUs\") will vest as follows: 50% of the RSUs vested on March 23, 2018, and the remaining 50% of the RSUs vested on March 23, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units (\"RSUs\") will vest as follows: 50% of the RSUs vested on March 23, 2018, and the remaining 50% of the RSUs vested on March 23, 2020."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-020979","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674905/000120919120020979/doc4.xml","form_type":"4"}},{"id":3196445,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-03-24T17:47:37.000Z","date":"2020-03-23","kind":"tax_withholding","acquired":false,"shares":6132,"price":2.82,"value":17292.24,"ownership":{"direct":true},"balance_after":30410,"source":{"system":"sec-edgar","filing":"0001209191-20-020979","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674905/000120919120020979/doc4.xml","form_type":"4"}},{"id":3196444,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-03-24T17:47:37.000Z","date":"2020-03-23","kind":"exercise","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of NantKwest, Inc. common stock."}],"balance_after":36542,"source":{"system":"sec-edgar","filing":"0001209191-20-020979","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674905/000120919120020979/doc4.xml","form_type":"4"}},{"id":3447205,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-08-05T17:46:19.000Z","date":"2019-08-02","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of NantKwest, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units (\"RSUs\") will vest as follows: 25% of the RSUs will vest on August 2, 2019, and 25% of the RSUs will vest annually thereafter, such that the award will be fully vested on August 2, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units (\"RSUs\") will vest as follows: 25% of the RSUs will vest on August 2, 2019, and 25% of the RSUs will vest annually thereafter, such that the award will be fully vested on August 2, 2022."}],"balance_after":30000,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-044647","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674905/000120919119044647/doc4.xml","form_type":"4"}},{"id":3447204,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-08-05T17:46:19.000Z","date":"2019-08-02","kind":"tax_withholding","acquired":false,"shares":3458,"price":1.27,"value":4391.66,"ownership":{"direct":true},"balance_after":21542,"source":{"system":"sec-edgar","filing":"0001209191-19-044647","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674905/000120919119044647/doc4.xml","form_type":"4"}},{"id":3447203,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-08-05T17:46:19.000Z","date":"2019-08-02","kind":"exercise","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of NantKwest, Inc. common stock."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001209191-19-044647","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674905/000120919119044647/doc4.xml","form_type":"4"}},{"id":3830606,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-08-29T20:58:56.000Z","date":"2018-08-27","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the award recipient's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the option shall vest as follows: twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on August 27, 2019, and thereafter the remaining shares subject to the option shall vest and become exercisable in equal monthly installments over thirty six (36) months, such that the option will be fully vested and exercisable on August 27, 2022."}],"balance_after":200000,"derivative":{"exercise_price":3.07,"expiration_date":"2028-08-27","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-18-048877","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674905/000120919118048877/doc4.xml","form_type":"4"}},{"id":3853314,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2018-08-03T17:40:01.000Z","date":"2018-08-02","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of NantKwest, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units (\"RSUs\") will vest as follows: 25% of the RSUs will vest on August 2, 2019, and 25% of the RSUs will vest annually thereafter, such that the award will be fully vested on August 2, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units (\"RSUs\") will vest as follows: 25% of the RSUs will vest on August 2, 2019, and 25% of the RSUs will vest annually thereafter, such that the award will be fully vested on August 2, 2022."}],"balance_after":40000,"derivative":{"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-18-045353","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674905/000120919118045353/doc4.xml","form_type":"4"}},{"id":3983057,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Restricted Stock Units","published_at":"2018-03-26T18:55:10.000Z","date":"2018-03-23","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of NantKwest, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units (\"RSUs\") will vest as follows: 50% of the RSUs vested on March 23, 2018, and the remaining 50% of the RSUs will vest on March 23, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units (\"RSUs\") will vest as follows: 50% of the RSUs vested on March 23, 2018, and the remaining 50% of the RSUs will vest on March 23, 2020."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-18-021664","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674905/000120919118021664/doc4.xml","form_type":"4"}},{"id":3983056,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":93101,"kind":"person","name":"Nelson Sonja","position":1,"cik":"0001674905","reported_name":"Nelson Sonja","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2018-03-26T18:55:10.000Z","date":"2018-03-23","kind":"exercise","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units (\"RSUs\") will vest as follows: 50% of the RSUs vested on March 23, 2018, and the remaining 50% of the RSUs will vest on March 23, 2020."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-18-021664","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674905/000120919118021664/doc4.xml","form_type":"4"}}]}